Figure 5
Leukemia xenograft regression and survival after PRIT with 213Bi- or 90Y-DOTA-biotin at equivalent absorbed doses. Athymic mice bearing HEL xenografts were injected intravenously via tail vein 2 days after tumor cell implantation with 1.4 nmol of anti-CD45 Ab-SA conjugate followed 22 hours later with 5.8 nmol of CA and subsequently with 1.2 nmol of radiolabeled DOTA-biotin 3 hours later to deliver an absorbed dose of 10 Gy from each radionuclide delivered to the liver (112 μCi 90Y-DOTA-biotin and 800 μCi 213Bi-DOTA-biotin). Control tumor-bearing control mice were untreated. (A) Tumor volume curves are not truncated. (B) Mice were also analyzed for survival as a function of time.
